Clinical Trials

List clinical trials by disease

Search Clinical Trials

The results of your search are listed below. To view the details of a trial or study, click on the "see details >>" link. Or start a new search.

Searched for: Breast Cancer. 16 results shown below.

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer

[Complete title: Combined Targeted Therapies for Triple Negative Advanced Breast Cancer – A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy with Bevacizumab and Erlotinib]
Principal Investigator: Jennifer Specht, MD
Study Number: 6628
Phase: II

Vaccine Therapy in Treating Patients With Stage IV Breast Cancer

[Complete title: Phase I/II Study of Adoptive T Cell Therapy Following In Vivo Priming With a HER-2/neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine in Patients With Advanced Stage HER2 Overexpressing Breast Cancer]
Principal Investigator: Nora Disis, MD
Study Number: 6658
Phase: I/II

High-dose Methotrexate and Liposomal Cytarabine in Treating Patients With CNS Metastases From Breast Cancer

[Complete title: Phase II Study of the Combination of High-dose Methotrexate and Intrathecal Liposomal Cytarabine in Patients with Leptomeningeal Metastases with or without Parenchymal Brain Involvement]
Principal Investigator: Maciej Mrugala, MD, PhD
Study Number: 6954
Phase: II

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

[Complete title: Phase I Study of ABT-888 in Combination with Cisplatin and Vinorelbine for Patients with Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer]
Principal Investigator: John Thompson, MD
Study Number: 7161
Phase: I

Vaccine Therapy in Combination With Ampligen® and/or Sargramostim in Patients With Stage II-IV HER2-Positive Breast Cancer

[Complete title: Phase I-II Study of HER2 Vaccination with poly(I)* poly(C12U) (Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients]
Principal Investigator: Lupe Salazar, MD
Study Number: 7425
Phase: I/II

I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

[Complete title: I-SPY2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and moLecular Analysis 2)]
Principal Investigator: Larissa Korde
Study Number: 7518
Phase: II

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy

[Complete title: A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy Part B]
Principal Investigator: Hannah Linden, MD
Study Number: 7841
Phase: Pilot

Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer

[Complete title: Phase II Study to Evaluate the Development of HER2/neu (HER2)-Specific Memory T Cells After HER2 Peptide-Based Vaccination in Patients with Advanced Stage HER2+ Breast Cancer]
Principal Investigator: Lupe Salazar, MD
Study Number: 7905
Phase: II

Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

[Complete title: Donor Statin Treatment for Prevention of Severe Acute GVHD after Myeloablative Hematopoietic Cell Transplantation]
Principal Investigator: Marco Mielcarek, MD
Study Number: 2545.00
Phase: II

A Phase III Trial of Accelerated Whole Breast Irradiation With Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost For Early-Stage Breast Cancer
Principal Investigator: George Laramore, MD, PhD
Study Number: 7585
Phase: III

A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I or II Breast Cancer
Principal Investigator: Tanya Wahl, MD
Study Number: NSABP B-39
Phase: III

A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy
Principal Investigator: Tanya Wahl, MD
Study Number: NSABP B-43
Phase: III

A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Principal Investigator: Tanya Wahl, MD
Study Number: NSABP B-47
Phase: III

The BEACON Study (Breast Cancer Outcomes With NKTR-102)

[Complete title: The BEACON Study (BrEAst Cancer Outcomes with NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician’s Choice (TPC) in Patients with Locally Recurrent or Metastatic Breast Cancer Previously Treated with an Anthracycline, a Taxane, and Capecitabine]
Principal Investigator: Jennifer Specht, MD
Study Number: 20111824
Phase: III

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

[Complete title: A Two-Cohort, Open-Label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination with Trastuzumab and Vinorelbine in First Line Patients with HER2-Positive Advanced (Metastatic or Locally Advanced) Breast Cancer]
Principal Investigator: Jennifer Specht, MD
Study Number: 20121111
Phase: II

MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

[Complete title: Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients with Ovarian or Breast Cancer]
Principal Investigator: Barbara Ann Goff, MD
Study Number: 7527
Phase: I/II

Search Options

Select a disease from the list below:
Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:
Limit results to studies enrolling:

OR

View all studies
Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.